CN104490815A - Chewable tablet prepared from bismuth potassium citrate composition and preparation method thereof - Google Patents
Chewable tablet prepared from bismuth potassium citrate composition and preparation method thereof Download PDFInfo
- Publication number
- CN104490815A CN104490815A CN201410735514.1A CN201410735514A CN104490815A CN 104490815 A CN104490815 A CN 104490815A CN 201410735514 A CN201410735514 A CN 201410735514A CN 104490815 A CN104490815 A CN 104490815A
- Authority
- CN
- China
- Prior art keywords
- chewable tablet
- medicinal liquid
- drug
- potassium citrate
- bismuth potassium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 title claims abstract description 47
- 229940068682 chewable tablet Drugs 0.000 title claims abstract description 39
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 43
- 229940079593 drug Drugs 0.000 claims abstract description 31
- 239000005720 sucrose Substances 0.000 claims abstract description 16
- 229920002472 Starch Polymers 0.000 claims abstract description 10
- 239000008107 starch Substances 0.000 claims abstract description 10
- 235000019698 starch Nutrition 0.000 claims abstract description 10
- 229930006000 Sucrose Natural products 0.000 claims abstract description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 238000010792 warming Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 9
- 229920002261 Corn starch Polymers 0.000 claims description 8
- 239000008120 corn starch Substances 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000003002 pH adjusting agent Substances 0.000 claims description 5
- 229920000742 Cotton Polymers 0.000 claims description 4
- 239000005030 aluminium foil Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 229940055365 potassium citrate chewable tablet Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- -1 oral solution Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a chewable tablet prepared from a bismuth potassium citrate composition and a preparation method thereof and belongs to the technical field of medicines and medicine production. The chewable tablet is prepared from bismuth potassium citrate, starch and sucrose, overcomes the defects of the ordinary chewable tablet and is prepared by adopting a few kinds of and a small amount of adjuvants compared with the chewable tablet prepared from bismuth potassium citrate. The medicinal preparation has excellent performance, high bioavailability, good stability and high patient acceptance, has no sense of grit and has important clinical application value.
Description
Technical field
The present invention relates to medicine and medical production technical field, be specifically related to a kind of bismuth potassium citrate compositions chewable tablet and preparation method thereof.
Background technology
Tablet quality is stable, taking convenience, is basic, the most the most frequently used a kind of dosage form.But for the patient of child, old man and dysphagia, conventional tablet often takes difficulty, and Long-term taking medicine even can make it produce psychological phenomenon of refusing to take medicine, and chewable tablet then can remedy such and insufficient.Chewable tablet is the tablet under a class can chew posterior phraynx in oral cavity, and size is general identical with conventional tablet, can make difform Special-shaped sheet as required.Tablet is convenient to swallow after chewing, and coat tablets is long-pending to be increased, and can promote medicine dissolving in vivo, absorption.For the medicine of difficult disintegrate, make chewable tablet and can accelerate its disintegrate, improve drug effect.Chewable tablet taking convenience, even if also can medication on time under the condition of hydropenia, be specially adapted to the patient that children's, old man, dysphagia or gastrointestinal function are poor, can reduces medicine and bear gastrointestinal.Therefore, chewable tablet application is extensively got up gradually.
Bismuth potassium citrate is a kind ofly form indefinite bismuth-containing complex, is gastric mucosa protectant.The protective layer forming dispersivity in gastric acid condition is covered on ulcer surface, stops gastric acid, enzyme and food to the invasion and attack of ulcer, promotes ulcerated mucosa regeneration and ulcer healing.Also there is effects such as reducing pepsic activity, increase mucin secretion, promotion mucosa release PGE2, thus protection gastric mucosa, this product has killing action to helicobacter pylori (Hp) in addition, thus can promote the healing of gastritis.
The pharmaceutical preparation of the bismuth potassium citrate gone on the market has conventional tablet, oral solution, granule, chewable tablet, capsule etc., wherein bismuth potassium citrate chewable tablet supplementary product kind and quantity more, generally to use filler, lubricant, disintegrating agent, adhesive, correctives etc., and at least will use 4 kinds of adjuvants.Increasing research shows that impurity in the incompatibility of the toxic and side effects of adjuvant itself, adjuvant and principal agent, adjuvant etc. all can have an impact to the safety of medicine.
Therefore, select suitable adjuvant and technique, reduce supplementary product kind and the consumption of bismuth potassium citrate chewable tablet, improve the stability of bismuth potassium citrate chewable tablet, for ensureing that the safety of clinical application has positive effect.
Starch is polymerized by glucose molecule, it is the basic adjuvant of oral solid formulation, be usually used in chewable tablet, making adhesive, diluent and disintegrating agent, and starch all extracts from the natural materials such as Semen Maydis, Maninot esculenta crantz., safe and reliable, cheap and easy to get, but being used alone starch has no report as adjuvant for the production of chewable tablet.
Summary of the invention
Technical problem to be solved by this invention is the defect overcoming prior art, and propose a kind of bismuth potassium citrate compositions chewable tablet and preparation method thereof further, said preparation adjuvant is few, good stability, and bioavailability is high.
Technical problem to be solved by this invention realizes by the following technical solutions:
A kind of bismuth potassium citrate compositions chewable tablet, comprise bismuth potassium citrate, starch, sucrose, this tablet overcomes the shortcoming of above-mentioned common chewable tablet, decrease supplementary product kind and consumption in bismuth potassium citrate chewable tablet, this pharmaceutical preparation function admirable, bioavailability is high, have good stability, patient acceptance is high, without sand type, has important clinical value.
A kind of bismuth potassium citrate compositions chewable tablet, is prepared from by following raw material:
A preparation method for bismuth potassium citrate compositions chewable tablet, comprises step as follows:
A, take the starch of component amount, add a certain amount of purified water and stir, by pH adjusting agent, the pH value of solution is controlled between 7 ~ 9, be then heated to 72 DEG C, be incubated 120 minutes, make the gelatinizing corn starch solution of 5 ~ 15% (W/V);
B, measure purified water 45ml, boil, add 85g sucrose, stir, after dissolving, continue to be heated to 100 DEG C, filter with purified cotton, the appropriate hot distilled water of filter is cleaned, and washing liquid and filtrate merge, and let cool, add appropriate distilled water, make full dose become 100mL, stir evenly, obtain B solution;
The solution that C, the medicinal liquid and the step B that steps A are obtained obtain mixes, and fully stirs 30 minutes, after medicinal liquid be down to room temperature obtain gelatinizing Semen Maydis-sucrose system medicinal liquid;
D, take bismuth potassium citrate 300g, add 1L gelatinizing Semen Maydis-sucrose system medicinal liquid, stir 25 ~ 35 minutes;
E, the medicinal liquid sampling and measuring bismuth citrate potassium content obtained step D, control with sodium hydroxide or hydrochloric acid between 7.0 ~ 9.0 by pH value;
After bismuth citrate potassium content measured by F, medicinal liquid, be sub-packed in drug-containing dish by loading amount by medicinal liquid, each drug-containing dish fills about 1.0ml, then utilizes drug-containing dish lid malcompression state to cover drug-containing dish, and drug-containing dish is the cylindric medicine carrying packaging that plastics or other materials are made;
G, the drug-containing dish that medicinal liquid is housed is put into freeze drying box, be cooled to subzero 45 DEG C, keep 2 hours, evacuation, then 0 DEG C is warming up to gradually, keep 2 hours, then be cooled to subzero 45 DEG C, keep 2 hours, be warming up to 0 DEG C gradually again, keep 2 ~ 4 hours, then be warming up to 28 ~ 32 DEG C of dryings 4 ~ 6 hours gradually, whole process vacuum remains on below 10 handkerchiefs; Finally the drug-containing dish lid of powder charge is covered tightly, and load aluminium foil bag and carry out sealing and obtain bismuth potassium citrate compositions chewable tablet.
The preparation method of a kind of bismuth potassium citrate compositions chewable tablet of the present invention, in described steps A, pH adjusting agent is sodium hydroxide or hydrochloric acid, preferably controls 8.5 by the pH value of solution; Mixing time preferably 30 minutes in step C; In step D, pH value preferably controls 8.0, is preferably warming up to 0 DEG C gradually again in step F, keeps 3 hours, then is warming up to 30 DEG C of dryings 5 hours gradually; Described starch selects corn starch.
Beneficial effect of the present invention is:
The preparation method of a kind of bismuth potassium citrate compositions chewable tablet of the present invention, it adopts unique processing step, carries out special process process, can improve the bonding of starch in chewable tablet, disintegration to common corn starch, improves the molding of chewable tablet.And dosage of sucrose is 8.5% (W/V) in bismuth potassium citrate compositions chewable tablet, it is the hardness reinforcer of this tablet, and plays flavored action.Bismuth potassium citrate compositions chewable tablet only needs starch and sucrose two kinds of adjuvants, reduces the kind of required adjuvant; Because the technique of two liters falls in freeze-dry process employing two, twice cooling, twice intensification can make chewable tablet mouldability better, and improve stability and the quality of product.Therefore the preparation method of a kind of bismuth potassium citrate compositions chewable tablet provided by the invention has easy to operate, and prescription is simple, and technique is unique, the feature that product stability, safety are high.
Detailed description of the invention
The technological means realized to make the present invention, creation characteristic, reaching object and effect is easy to understand, below in conjunction with specific embodiment, set forth the present invention further, but following embodiment being only the preferred embodiments of the present invention, and not all.Based on the embodiment in embodiment, those skilled in the art under the prerequisite not making creative work obtain other embodiment, all belong to the protection domain of this patent.
Bismuth citrate potassium content is for 300mg/ sheet.
Embodiment 1
Prescription: 1000 amounts
A, take the corn starch of 100g, the purified water adding 900ml stirs, and controls 8.5, is then heated to 72 DEG C, keep 120 minutes, make the gelatinizing corn starch solution of about 10% (W/V) by pH adjusting agent by the pH value of solution.
B, measure purified water 45ml, boil, add 85g sucrose, stir, after dissolving, continue to be heated to 100 DEG C, filter with purified cotton, the appropriate hot distilled water of filter is cleaned, and washing liquid and filtrate merge, and let cool, add appropriate distilled water, make full dose become 100mL, stir evenly, obtain B solution.
The solution that C, the medicinal liquid and the step B that steps A are obtained obtain mixes, and fully stirs 30 minutes, after medicinal liquid be down to room temperature obtain gelatinizing Semen Maydis-sucrose system medicinal liquid.
D, take bismuth potassium citrate 300g (by 1000 calculations), add 1L gelatinizing Semen Maydis-sucrose system medicinal liquid, stir 30 minutes.
E, the medicinal liquid sampling and measuring bismuth citrate potassium content obtained step D, control pH value 8.0 with sodium hydroxide or hydrochloric acid.
After bismuth citrate potassium content measured by F, medicinal liquid, be sub-packed in drug-containing dish by loading amount by medicinal liquid, each drug-containing dish fills about 1.0ml, then utilizes drug-containing dish lid malcompression state to cover drug-containing dish, and drug-containing dish is the cylindric medicine carrying packaging that plastics or other materials are made.
G, the drug-containing dish that medicinal liquid is housed is put into freeze drying box, be cooled to subzero 45 DEG C, keep 2 hours, evacuation, then 0 DEG C is warming up to gradually, keep 2 hours, be cooled to subzero 45 DEG C, keep 2 hours, be warming up to 0 DEG C gradually again, keep 3 hours, then be warming up to 30 DEG C of dryings 5 hours gradually, whole process vacuum remains on below 10 handkerchiefs; Finally the drug-containing dish lid of powder charge is covered tightly, and load aluminium foil bag and carry out sealing and obtain a kind of bismuth potassium citrate compositions chewable tablet.
Embodiment 2
Prescription: 1000 amounts
A, take the corn starch of 150g, the purified water adding 900ml stirs, and controls 8.5, is then heated to 72 DEG C, keep 120 minutes, make the gelatinizing corn starch solution of about 5 ~ 15% (W/V) by pH adjusting agent by the pH value of solution.
B, measure purified water 45ml, boil, add 85g sucrose, stir, after dissolving, continue to be heated to 100 DEG C, filter with purified cotton, the appropriate hot distilled water of filter is cleaned, and washing liquid and filtrate merge, and let cool, add appropriate distilled water, make full dose become 100mL, stir evenly, obtain B solution.
The solution that C, the medicinal liquid and the step B that steps A are obtained obtain mixes, and fully stirs 30 minutes, after medicinal liquid be down to room temperature obtain gelatinizing Semen Maydis-sucrose system medicinal liquid.
D, take bismuth potassium citrate 300g (by 1000 calculations), add 1L gelatinizing Semen Maydis-sucrose system medicinal liquid, stir 30 minutes.
E, the medicinal liquid sampling and measuring bismuth citrate potassium content obtained step D, control pH value 8.0 with sodium hydroxide or hydrochloric acid.
After bismuth citrate potassium content measured by F, medicinal liquid, be sub-packed in drug-containing dish by loading amount by medicinal liquid, each drug-containing dish fills about 1.0ml, then utilizes drug-containing dish lid malcompression state to cover drug-containing dish, and drug-containing dish is the cylindric medicine carrying packaging that plastics or other materials are made.
G, the drug-containing dish that medicinal liquid is housed is put into freeze drying box, be cooled to subzero 45 DEG C, keep 2 hours, evacuation, then 0 DEG C is warming up to gradually, keep 2 hours, be cooled to subzero 45 DEG C, keep 2 hours, be warming up to 0 DEG C gradually again, keep 3 hours, then be warming up to 30 DEG C of dryings 5 hours gradually, whole process vacuum remains on below 10 handkerchiefs; Finally the drug-containing dish lid of powder charge is covered tightly, and load aluminium foil bag and carry out sealing and obtain a kind of bismuth potassium citrate compositions chewable tablet.
Experimental data
The bismuth potassium citrate compositions chewable tablet that above-described embodiment is obtained carries out following quality research test:
1, hardness, friability, mouthfeel contrast test
The bismuth potassium citrate compositions chewable tablet prepared according to above-described embodiment and commercially available bismuth potassium citrate chewable tablet (commercially available) detect friability and hardness by " Chinese Pharmacopoeia " version in 2010 two annex X G inspection techniques, contrast, the results are shown in following table:
| Sample | Hardness/N | Friability | Mouthfeel |
| Embodiment 1 | 62.1 | <1％ | Without grains of sand sense, crisp |
| Embodiment 2 | 67.2 | <1％ | Without grains of sand sense, crisp |
| Ordinary tablet | 75.3 | <1％ | There is grains of sand sense, more firmly |
Experimental data shows, the more commercially available bismuth potassium citrate chewable tablet of bismuth potassium citrate compositions chewable tablet on friability and hardness without significant difference, meet " Chinese Pharmacopoeia " version in 2010 to the requirement of chewable tablet, and mouthfeel is greatly improved, make it the demand more meeting patient.
2, stability study
Sample source: self-control
Sample lot number: 20130701 (embodiments 1), 20130702 (embodiments 2)
Investigation project: character, content, hardness
Investigation method: according to " Chinese Pharmacopoeia " version in 2010 two annex XIX C crude drug and pharmaceutical preparation stability test guideline, investigate the accelerated stability (January, February, March, June) of this product and long-time stability (March, June, JIUYUE, December), result of the test is as following table:
As can be seen from the above table, in acceleration 6 months, all there is not significant change in long-term 12 months, show that this product has good stability in bismuth potassium citrate compositions chewable tablet indices of the present invention.
More than show and describe ultimate principle of the present invention, principal character and advantage of the present invention.The technical staff of the industry should understand; the present invention is not restricted to the described embodiments; what describe in above-described embodiment and description is only preference of the present invention; be not used for limiting the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications, and these changes and improvements all fall in the claimed scope of the invention.Application claims protection domain is defined by appending claims and equivalent thereof.
Claims (2)
1. a bismuth potassium citrate compositions chewable tablet, is characterized in that, is prepared from by following raw material:
2. a preparation method for bismuth potassium citrate compositions chewable tablet according to claim 1, is characterized in that, comprise step as follows:
A, take the starch of component amount, add a certain amount of purified water and stir, by pH adjusting agent, the pH value of solution is controlled between 7 ~ 9, be then heated to 72 DEG C, be incubated 120 minutes, make the gelatinizing corn starch solution of 5 ~ 15% (W/V);
B, measure purified water 45ml, boil, add 85g sucrose, stir, after dissolving, continue to be heated to 100 DEG C, filter with purified cotton, the appropriate hot distilled water of filter is cleaned, and washing liquid and filtrate merge, and let cool, add appropriate distilled water, make full dose become 100mL, stir evenly, obtain B solution;
The solution that C, the medicinal liquid and the step B that steps A are obtained obtain mixes, and fully stirs 30 minutes, after medicinal liquid be down to room temperature obtain gelatinizing Semen Maydis-sucrose system medicinal liquid;
D, take bismuth potassium citrate 300g, add 1L gelatinizing Semen Maydis-sucrose system medicinal liquid, stir 25 ~ 35 minutes;
E, the medicinal liquid sampling and measuring bismuth citrate potassium content obtained step D, control with sodium hydroxide or hydrochloric acid between 7.0 ~ 9.0 by pH value;
After bismuth citrate potassium content measured by F, medicinal liquid, be sub-packed in drug-containing dish by loading amount by medicinal liquid, each drug-containing dish fills about 1.0ml, then utilizes drug-containing dish lid malcompression state to cover drug-containing dish, and drug-containing dish is the cylindric medicine carrying packaging that plastics or other materials are made;
G, the drug-containing dish that medicinal liquid is housed is put into freeze drying box, be cooled to subzero 45 DEG C, keep 2 hours, evacuation, then 0 DEG C is warming up to gradually, keep 2 hours, then be cooled to subzero 45 DEG C, keep 2 hours, be warming up to 0 DEG C gradually again, keep 2 ~ 4 hours, then be warming up to 28 ~ 32 DEG C of dryings 4 ~ 6 hours gradually, whole process vacuum remains on below 10 handkerchiefs; Finally the drug-containing dish lid of powder charge is covered tightly, and load aluminium foil bag and carry out sealing and obtain bismuth potassium citrate compositions chewable tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410735514.1A CN104490815A (en) | 2014-12-05 | 2014-12-05 | Chewable tablet prepared from bismuth potassium citrate composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410735514.1A CN104490815A (en) | 2014-12-05 | 2014-12-05 | Chewable tablet prepared from bismuth potassium citrate composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104490815A true CN104490815A (en) | 2015-04-08 |
Family
ID=52932333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410735514.1A Pending CN104490815A (en) | 2014-12-05 | 2014-12-05 | Chewable tablet prepared from bismuth potassium citrate composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104490815A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129532A (en) * | 2021-12-10 | 2022-03-04 | 丽珠集团丽珠制药厂 | Bismuth potassium citrate preparation |
-
2014
- 2014-12-05 CN CN201410735514.1A patent/CN104490815A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129532A (en) * | 2021-12-10 | 2022-03-04 | 丽珠集团丽珠制药厂 | Bismuth potassium citrate preparation |
| CN114129532B (en) * | 2021-12-10 | 2023-09-19 | 丽珠集团丽珠制药厂 | A kind of bismuth potassium citrate preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104490925A (en) | Vitamin D calcium composition chewable tablets and preparation method thereof | |
| CN104586881A (en) | Sodium bicarbonate composition freeze-dried tablet and preparation method thereof | |
| CN102772383A (en) | Azithromycin composition freeze-dried orally disintegrating tablet and preparation method thereof | |
| CN104490815A (en) | Chewable tablet prepared from bismuth potassium citrate composition and preparation method thereof | |
| CN104490814A (en) | Zinc gluconate composition chewable tablets and preparation method thereof | |
| CN104490924A (en) | Sucralfate composition chewable tablets and preparation method thereof | |
| CN104434972A (en) | Calcium hydrophosphate composite chewable tablet and preparation method thereof | |
| CN102525979B (en) | Infant ibuprofen composition | |
| CN104490804A (en) | Cimetidine composition chewable tablets and preparation method thereof | |
| CN104490813A (en) | Dextromethorphan hydrobromide composition chewable tablets and preparation method thereof | |
| CN104490811A (en) | Aspirin composition chewable tablet and preparation method thereof | |
| CN104490816A (en) | Chewable tablet prepared from ferrous fumarate composition and preparation method thereof | |
| CN104490805A (en) | Simvastatin composition chewable tablets and preparation method thereof | |
| CN104490807A (en) | Ambroxol hydrochloride composition chewable tablet and preparation method thereof | |
| CN104523613A (en) | Montelukast sodium composition chewable tablet and preparation method thereof | |
| CN104434834A (en) | Mebendazole composition chewable tablet and preparation method thereof | |
| CN104490819A (en) | Loratadine composition chewable tablets and preparation method thereof | |
| CN104490926A (en) | Calcium carbonate composition chewable tablet and preparation method thereof | |
| CN104490820A (en) | Gentamicin sulfate composition chewable tablets and preparation method thereof | |
| CN104606155A (en) | Metoclopramide composition freeze-dried tablet and preparation method thereof | |
| CN104490808A (en) | Cefixime composition chewable tablets and preparation method thereof | |
| CN103239478A (en) | Calcium carbonate milk composition freeze-dried orally disintegrating tablets, and preparation method thereof | |
| CN104523612A (en) | Calcium lactate composition chewable tablet and preparation method thereof | |
| CN104490806A (en) | Vitamin C composition chewable tablets and preparation method thereof | |
| CN104523614A (en) | Vitamin B6 composition freeze-dried tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150408 |